Sylvain Jereme M 4

What Happened

• Sylvain Jereme, EVP and Chief Financial Officer of DexCom, was granted 48,774 restricted stock units (RSUs) on March 8, 2026 (grant reported on Form 4). On the same date, 18,950 shares were withheld to satisfy tax withholding obligations at an effective withholding price of $68.10 per share, totaling $1,290,495. The RSUs were granted at $0.00 (typical for RSUs) and vest in three equal annual installments.

Key Details

• Transaction date: 2026-03-08; filing date: 2026-03-10 (timely).
• Grant: 48,774 RSUs (code A) — RSUs are a contingent right to receive one share each upon vesting.
• Tax withholding: 18,950 shares withheld (code F) at $68.10/share = $1,290,495; this withholding is to cover tax obligations and does not represent an open-market sale by the reporting person.
• Shares owned after transaction: not specified in the filing.
• Notable footnotes: RSUs are exempt under Section 16b-3 and vest in three equal annual installments (footnote F1). Footnote F3 indicates the reporting person has 92,794 unvested RSUs in total (including the 48,774 granted Mar 8, 2026) plus 261 shares from the ESPP.

Context

• RSU grants are compensation awards and typically indicate retention/incentive arrangements rather than a market-direction bet. The withholding of shares to cover taxes (net settlement) is a routine administrative step and should not be read as a sell signal.